Defence Therapeutics Inc. · ISIN: CA24463V1013 · EQS - Company News

DEFENCE THERAPEUTICS GRANTED CNRI-H FROM THE CANADIAN NUCLEAR LABORATORIES TO ACCELERATE THE DEVELOPMENT OF ITS RADIO-IMMUNO-CONJUGATES PROGRAM

  _________________________________________________________________ CSE: DTC  FSE: DTC  USOTC: DTCFF  PRESS RELEASE   DEFENCE THERAPEUTICS GRANTED CNRI-H FROM THE CANADIAN NUCLEAR LABORATORIES TO ACCELERATE THE DEVELOPMENT OF ITS RADIO-IMMUNO-CONJUGATES PROGRAM   Vancouver, BC, Canada, July 24th, 2024 - Defence Therapeutics Inc. (“Defence” or the “Company”), (CSE: DTC, OTCQB: DTCFF, FSE: DTC), a Canadian biopharmaceutical company developing novel immune-oncology vaccines and drug delivery...

CSE:DTC Price indication powered by TradingView

About the publication

Corporate Insights - Short Sales, Director's Dealings, Sentiment Indicators - THE info hub for the informed investor

Smart tools for smart investors can be found in our Tools section

Corporate News Defence Therapeutics Inc.

In this overview you can view company news in the chronological order of publication. The source information comes from EQS News, the leading European news distributor. The most recent news item is listed first.
Back to Corporate News Overview
This might be interesting for you as well
Analyst Ratings (6)
Directors Dealings (0)
Short Selling (DE) (0)
Short Selling (UK) (0)
24 July 2024 08:00AM
DEFENCE THERAPEUTICS GRANTED CNRI-H FROM THE CANADIAN NUCLEAR LABORATORIES TO ACCELERATE THE DEVELOPMENT OF ITS RADIO-IMMUNO-CONJUGATES PROGRAM
CA24463V1013
  _________________________________________________________________ CSE: DTC  FSE: DTC  USOTC: DTCFF  PRESS RELEASE   DEFENCE THERAPEUTICS GRANTED CNRI-H FROM THE CANADIAN NUCLEAR LABORATORIES TO ACCELERATE THE DEVELOPMENT OF ITS RADIO-IMMUNO-CONJUGATES PROGRAM   Vancouver, BC, Canada, July 24th, 2024 - Defence Therapeutics Inc. (“Defence” o...
Defence Therapeutics Inc.
About the publication
08 July 2024 08:00AM
DEFENCE RECEIVES NO OBJECTION LETTER FROM HEALTH CANADA FOR PHASE I TRIAL OF ITS ACCUM-002 (ACCUTOX) AS AN ANTI-CANCER MOLECULE IN PATIENTS WITH MELANOMA
CA24463V1013
  _________________________________________________________________ CSE: DTC  FSE: DTC  USOTC: DTCFF  PRESS RELEASE   DEFENCE RECEIVES NO OBJECTION LETTER FROM HEALTH CANADA FOR PHASE I TRIAL OF ITS ACCUM-002 (ACCUTOX) AS AN ANTI-CANCER MOLECULE IN PATIENTS WITH MELANOMA   Vancouver, BC, Canada, July 8th, 2024 - Defence Therapeutics Inc. (“...
Defence Therapeutics Inc.
About the publication
10 June 2024 08:00AM
DEFENCE TO PARTICIPATE TO 2024 SOCIETY OF NUCLEAR MEDICINE AND MOLECULAR IMAGING ANNUAL MEETING IN TORONTO ON JUNE 11, 2024
CA24463V1013
  _________________________________________________________________ CSE: DTC  FSE: DTC  USOTC: DTCFF  PRESS RELEASE   DEFENCE TO PARTICIPATE TO 2024 SOCIETY OF NUCLEAR MEDICINE AND MOLECULAR IMAGING ANNUAL MEETING IN TORONTO ON JUNE 11, 2024   Vancouver, BC, Canada, June 10th, 2024 - Defence Therapeutics Inc. (“Defence” or the “Company”), (...
Defence Therapeutics Inc.
About the publication
14 May 2024 08:00AM
DEFENCE THERAPEUTICS STRENGTHENS AND EXPANDS GLOBAL PATENT PROTECTION ON KEY TECHNOLOGIES
CA24463V1013
CSE: DTC     FSE: DTC     USOTC: DTCFF     PRESS RELEASE DEFENCE THERAPEUTICS STRENGTHENS AND EXPANDS GLOBAL PATENT PROTECTION ON KEY TECHNOLOGIES  Vancouver, BC, Canada, May 14, 2024 - Defence Therapeutics Inc. (“Defence” or the “Company”), (CSE: DTC, OTCQB: DTCFF, FSE: DTC), a Canadian biopharmaceutical company developing novel immune-oncology ...
Defence Therapeutics Inc.
About the publication
02 May 2024 08:00AM
SUCCESFUL TRIAL AGAINST PANCREATIC CANCER WITH DEFENCE’S ARM-002 ANTI-CANCER VACCINE
CA24463V1013
  _________________________________________________________________ CSE: DTC  FSE: DTC  USOTC: DTCFF       PRESS RELEASE   PANCREACTIC CANCER: SUCCESFUL TRIAL AGAINST PANCREATIC CANCER WITH DEFENCE’S ARM-002 ANTI-CANCER VACCINE   Vancouver, BC, Canada, May 1st, 2024 - Defence Therapeutics Inc. (“Defence” or the “Company”), (CSE: DTC, OTCQB: D...
Defence Therapeutics Inc.
About the publication
26 March 2024 08:00AM
DEFENCE’S SUCCESSFUL RESULTS ON ITS  ACCUTOX® ANTI-CANCER ARMTM VACCINE CREATES A POTENT SECOND-GENERATION ANTI-CANCER ARM-002TM VACCINE
CA24463V1013
  _________________________________________________________________ CSE: DTC  FSE: DTC  OTCQB: DTCFF       PRESS RELEASE   DEFENCE’S SUCCESSFUL RESULTS ON ITS  ACCUTOX® ANTI-CANCER ARMTM VACCINE CREATES A POTENT SECOND-GENERATION ANTI-CANCER ARM-002TM VACCINE   Vancouver, BC, Canada, March 26th, 2024 - Defence Therapeutics Inc. (“Defence” or ...
Defence Therapeutics Inc.
About the publication
04 March 2024 08:00AM
DEFENCE THERAPEUTICS AWARDED BROAD U.S. PATENT COVERING ITS PIONEERING CANCER-KILLING ACCUTOX® TECHNOLOGY
CA24463V1013
_________________________________________________________________ CSE: DTC  FSE: DTC  USOTC: DTCFF  PRESS RELEASE    DEFENCE THERAPEUTICS AWARDED BROAD U.S. PATENT COVERING ITS PIONEERING CANCER-KILLING ACCUTOX® TECHNOLOGY   Vancouver, BC, Canada, March 4th, 2024 - Defence Therapeutics Inc. (“Defence” or the “Company”), a Canadian biopharmaceu...
Defence Therapeutics Inc.
About the publication
10 January 2024 08:00AM
DEFENCE’S ACCUTOX® IMPAIRS LUNG CANCER GROWTH
CA24463V1013
  _________________________________________________________________ CSE: DTC  FSE: DTC  USOTC: DTCFF       PRESS RELEASE   DEFENCE’S ACCUTOX® IMPAIRS LUNG CANCER GROWTH   Vancouver, BC, Canada, January 10th, 2024 - Defence Therapeutics Inc. (“Defence” or the “Company”), (CSE: DTC, OTCQB: DTCFF, FSE: DTC), one of the leading Canadian biotechno...
Defence Therapeutics Inc.
About the publication
12 December 2023 08:00AM
DEFENCE RECEIVES FDA APPROVAL FOR PHASE I CLINICAL TRIAL TARGETING SOLID CANCER TUMORS WITH ACCUTOX®
CA24463V1013
  _________________________________________________________________ CSE: DTC  FSE: DTC  USOTC: DTCFF       PRESS RELEASE   DEFENCE RECEIVES FDA APPROVAL FOR PHASE I CLINICAL TRIAL TARGETING SOLID CANCER TUMORS WITH ACCUTOX®   Vancouver, BC, Canada, December 11th, 2023 - Defence Therapeutics Inc. (“Defence” or the “Company”), (CSE: DTC, USOTC:...
Defence Therapeutics Inc.
About the publication
14 November 2023 08:00AM
DEFENCE’S SUCCESSFUL SUBMISSION OF AN INVESTIGATIONAL NEW DRUG (IND) APPLICATION FOR ACCUTOX® AS AN INJECTABLE ANTICANCER TREATMENT FOR SOLID TUMORS
CA24463V1013
_________________________________________________________________ CSE: DTC  FSE: DTC  USOTC: DTCFF       PRESS RELEASE   DEFENCE’S SUCCESSFUL SUBMISSION OF AN INVESTIGATIONAL NEW DRUG (IND) APPLICATION FOR ACCUTOX® AS AN INJECTABLE ANTICANCER TREATMENT FOR SOLID TUMORS   Vancouver, BC, Canada, November 14th, 2023 - Defence Therapeutics Inc. (“...
Defence Therapeutics Inc.
About the publication
07 November 2023 08:00AM
DEFENCE THERAPEUTICS KEY PLATFORM PATENT ACCEPTED BROADLY COVERING VACCINE TECHNOLOGY
CA24463V1013
CSE: DTC          FSE: DTC          USOTC: DTCFF          PRESS RELEASE     DEFENCE THERAPEUTICS KEY PLATFORM PATENT ACCEPTED BROADLY COVERING VACCINE TECHNOLOGY   Vancouver, BC, Canada, November 7th, 2023 – Defence Therapeutics Inc. (“Defence” or the “Company”), (CSE: DTC, USOTC: DTCFF, FSE: DTC) a Canadian biopharmaceutical company developin...
Defence Therapeutics Inc.
About the publication
25 October 2023 08:00AM
DISCOVERY LEADS TOWARDS THE DEVELOPMENT OF A GROUDNBREAKING PLATFORM
CA24463V1013
CSE: DTC  FSE: DTC  USOTC: DTCFF       PRESS RELEASE   DEFENCE’S ACCUTOX®AND ANTIGEN CROSS-PRESENTATION: DISCOVERY LEADS TOWARDS THE DEVELOPMENT OF A GROUDNBREAKING PLATFORM   Vancouver, BC, Canada, October 25th, 2023 - Defence Therapeutics Inc. (“Defence” or the “Company”), a leading Canadian biopharmaceutical company specialized in the develop...
Defence Therapeutics Inc.
About the publication
18 October 2023 08:00AM
DEFENCE’S NOVEL ACCUTOXTM CONTINUES TO SURPRISE ON RESULTS AGAINST CANCER
CA24463V1013
  _________________________________________________________________ CSE: DTC  FSE: DTC  USOTC: DTCFF        PRESS RELEASE     DEFENCE’S NOVEL ACCUTOXTM CONTINUES TO SURPRISE ON RESULTS AGAINST CANCER   Vancouver, BC, Canada, October 17th, 2023 - Defence Therapeutics Inc. (“Defence” or the “Company”), a Canadian biopharmaceutical company spec...
Defence Therapeutics Inc.
About the publication
17 October 2023 08:00AM
DELIVERY OF ENCAPSULATED ACCUTOXTM-CHITOSAN NANOPARTICLES TRIGGERS COMPLETE TUMOR REGRESSION IN ANIMALS WITH PRE-ESTABSLIHED SOLID LYMPHOMA
CA24463V1013
CSE: DTC  FSE: DTC  USOTC: DTCFF        PRESS RELEASE   DELIVERY OF ENCAPSULATED ACCUTOXTM-CHITOSAN NANOPARTICLES TRIGGERS COMPLETE TUMOR REGRESSION IN ANIMALS WITH PRE-ESTABSLIHED SOLID LYMPHOMA   Vancouver, BC, Canada, October 17th, 2023 - Defence Therapeutics Inc. (“Defence” or the “Company”), a Canadian biopharmaceutical company specialized...
Defence Therapeutics Inc.
About the publication
10 October 2023 08:00AM
DEFENCE ANNOUNCES PEER-REVIEWED PUBLICATION OF ITS PRECLINICAL DATA ON ACCUM® AS AN ANTI-CANCER MOLECULE IN THE JOURNAL OF CANCER SCIENCE
CA24463V1013
CSE: DTC  FSE: DTC  USOTC: DTCFF  Vancouver, BC, Canada, October 10th, 2023 - Defence Therapeutics Inc. (“Defence” or the “Company”), a biotechnology company developing various products for the immune-oncology vaccines and drug delivery technologies, is pleased to announce the publication of a peer-reviewed study on the anticancer properties of it...
Defence Therapeutics Inc.
About the publication
25 September 2023 08:00AM
DEFENCE’S ACCUM®-mRNA LIPID NANOPARTICLES ELICIT ANTIBODY RESPONSE 2X STRONGER THAN STANDARD mRNA VACCINES
CA24463V1013
  _________________________________________________________________ CSE: DTC  FSE: DTC  USOTC: DTCFF        PRESS RELEASE     DEFENCE’S ACCUM®-mRNA LIPID NANOPARTICLES ELICIT ANTIBODY RESPONSE 2X STRONGER THAN STANDARD mRNA VACCINES   Vancouver, BC, Canada, September 25th, 2023 - Defence Therapeutics Inc. (“Defence” or the “Company”), a Cana...
Defence Therapeutics Inc.
About the publication
12 September 2023 08:00AM
DEFENCE’S BROAD AND VERSATILE ACCUM® TECHNOLOGY PLATFORM FOCUS ON CANCER THERAPEUTICS
CA24463V1013
  _________________________________________________________________ CSE: DTC  FSE: DTC  USOTC: DTCFF       PRESS RELEASE   DEFENCE’S BROAD AND VERSATILE ACCUM® TECHNOLOGY PLATFORM FOCUS ON CANCER THERAPEUTICS   Vancouver, BC, Canada, September 12th, 2023 - Defence Therapeutics Inc. (“Defence” or the “Company”), one of the leading Canadian bio...
Defence Therapeutics Inc.
About the publication
05 September 2023 08:00AM
DEFENCE’S INNOVATIVE THERAPEUTICS FEATURED ON VIEWPOINT WITH DENNIS QUAID
CA24463V1013
CSE: DTC        FSE: DTC        USOTC: DTCFF        PRESS RELEASE   DEFENCE’S INNOVATIVE THERAPEUTICS FEATURED ON VIEWPOINT WITH DENNIS QUAID   Vancouver, BC, Canada, September 5, 2023 - Defence Therapeutics Inc. (“Defence” or the “Company”) a Canadian biopharmaceutical company developing novel immune-oncology vaccines and drug delivery techno...
Defence Therapeutics Inc.
About the publication
18 July 2023 08:00AM
Defence Therapeutics Inc.: DEFENCE SUCCESSFULLY COMPLETES THE FIRST MILESTONE OF ITS COLLABORATION AGREEMENT WITH ORANO
CA24463V1013
CSE: DTC                FSE: DTC                 USOTC: DTCFF                          PRESS RELEASE   DEFENCE SUCCESSFULLY COMPLETES THE FIRST MILESTONE OF ITS COLLABORATION AGREEMENT WITH ORANO   Vancouver, BC, Canada, July 18, 2023 – Defence Therapeutics Inc. (“Defence” or the “Company”), is pleased to announce that it has successfully reach...
Defence Therapeutics Inc.
About the publication
18 July 2023 08:00AM
DEFENCE SUCCESSFULLY COMPLETES THE FIRST MILESTONE OF ITS COLLABORATION AGREEMENT WITH ORANO
CA24463V1013
CSE: DTC                FSE: DTC                 USOTC: DTCFF                          PRESS RELEASE   DEFENCE SUCCESSFULLY COMPLETES THE FIRST MILESTONE OF ITS COLLABORATION AGREEMENT WITH ORANO   Vancouver, BC, Canada, July 18, 2023 – Defence Therapeutics Inc. (“Defence” or the “Company”), is pleased to announce that it has successfully reach...
Defence Therapeutics Inc.
About the publication
04 July 2023 08:00AM
DEFENCE AND VIEWPOINT WITH DENNIS QUAID JOIN FORCES TO EXPLORE BREAKTHROUGHS IN BIOTECHNOLOGY
CA24463V1013
_________________________________________________________________ CSE: DTC  FSE: DTC  USOTC: DTCFF  PRESS RELEASE   DEFENCE AND VIEWPOINT WITH DENNIS QUAID JOIN FORCES TO EXPLORE BREAKTHROUGHS IN BIOTECHNOLOGY   Vancouver, BC, Canada, July 4, 2023 - Defence Therapeutics Inc. (“Defence” or the “Company”) a Canadian biopharmaceutical company dev...
Defence Therapeutics Inc.
About the publication
04 July 2023 08:00AM
DEFENCE AND VIEWPOINT WITH DENNIS QUAID JOIN FORCES TO EXPLORE BREAKTHROUGHS IN BIOTECHNOLOGY
CA24463V1013
_________________________________________________________________ CSE: DTC  FSE: DTC  USOTC: DTCFF  PRESS RELEASE   DEFENCE AND VIEWPOINT WITH DENNIS QUAID JOIN FORCES TO EXPLORE BREAKTHROUGHS IN BIOTECHNOLOGY   Vancouver, BC, Canada, July 4, 2023 - Defence Therapeutics Inc. (“Defence” or the “Company”) a Canadian biopharmaceutical company dev...
Defence Therapeutics Inc.
About the publication
28 June 2023 05:21PM
DEFENCE PATENT PORTFOLIO AT THE FOREFRONT OF SUCCESS 
CA24463V1013
CSE: DTC      FSE: DTC      USOTC: DTCFF      PRESS RELEASE   DEFENCE PATENT PORTFOLIO AT THE FOREFRONT OF SUCCESS  Vancouver, BC, Canada, June 28, 2023 - Defence Therapeutics Inc. (“Defence” or the “Company”) is a Canadian biopharmaceutical company developing novel immune-oncology vaccines and drug delivery technologies. Sitting at the core of i...
Defence Therapeutics Inc.
About the publication
28 June 2023 05:21PM
Defence Therapeutics Inc.: DEFENCE PATENT PORTFOLIO AT THE FOREFRONT OF SUCCESS 
CA24463V1013
CSE: DTC      FSE: DTC      USOTC: DTCFF      PRESS RELEASE   DEFENCE PATENT PORTFOLIO AT THE FOREFRONT OF SUCCESS  Vancouver, BC, Canada, June 28, 2023 - Defence Therapeutics Inc. (“Defence” or the “Company”) is a Canadian biopharmaceutical company developing novel immune-oncology vaccines and drug delivery technologies. Sitting at the core of i...
Defence Therapeutics Inc.
About the publication
20 June 2023 08:00AM
DEFENCE’S PROPRIETARY ACCUM(TM) TECHNOLOGY FOR DELIVERY OF CRISPR/CAS GENOME-EDITING COMPLEXES PATENT APPLICATON PUBLISHED
CA24463V1013
CSE: DTC      FSE: DTC      USOTC: DTCFF      PRESS RELEASE  DEFENCE’S PROPRIETARY ACCUMTM TECHNOLOGY FOR DELIVERY OF CRISPR/CAS GENOME-EDITING COMPLEXES PATENT APPLICATON PUBLISHED  Vancouver, BC, Canada, June 20, 2023 - Defence Therapeutics Inc. (“Defence” or the “Company”), a Canadian biopharmaceutical company developing novel immune-oncology ...
Defence Therapeutics Inc.
About the publication
20 June 2023 08:00AM
DEFENCE’S PROPRIETARY ACCUM(TM) TECHNOLOGY FOR DELIVERY OF CRISPR/CAS GENOME-EDITING COMPLEXES PATENT APPLICATON PUBLISHED
CA24463V1013
CSE: DTC      FSE: DTC      USOTC: DTCFF      PRESS RELEASE  DEFENCE’S PROPRIETARY ACCUMTM TECHNOLOGY FOR DELIVERY OF CRISPR/CAS GENOME-EDITING COMPLEXES PATENT APPLICATON PUBLISHED  Vancouver, BC, Canada, June 20, 2023 - Defence Therapeutics Inc. (“Defence” or the “Company”), a Canadian biopharmaceutical company developing novel immune-oncology ...
Defence Therapeutics Inc.
About the publication
16 June 2023 08:00AM
DEFENCE MANUFACTURING OF ACCUTOXTM CGMP FINAL DRUG PRODUCT OPTIMIZATION FOR ITS PHASE I CLINICAL TRIAL AT CITY OF HOPE
CA24463V1013
Defence Therapeutics Inc. CSE: DTC     FSE: DTC     USOTC: DTCFF      PRESS RELEASE    DEFENCE MANUFACTURING OF ACCUTOXTM CGMP FINAL DRUG PRODUCT OPTIMIZATION FOR ITS PHASE I CLINICAL TRIAL AT CITY OF HOPE   Vancouver, BC, Canada, June 16th 2023 - Defence Therapeutics Inc. (“Defence” or the “Company”), a Canadian biopharmaceutical company spec...
Defence Therapeutics Inc.
About the publication
16 June 2023 08:00AM
DEFENCE MANUFACTURING OF ACCUTOXTM CGMP FINAL DRUG PRODUCT OPTIMIZATION FOR ITS PHASE I CLINICAL TRIAL AT CITY OF HOPE
CA24463V1013
Defence Therapeutics Inc. CSE: DTC     FSE: DTC     USOTC: DTCFF      PRESS RELEASE    DEFENCE MANUFACTURING OF ACCUTOXTM CGMP FINAL DRUG PRODUCT OPTIMIZATION FOR ITS PHASE I CLINICAL TRIAL AT CITY OF HOPE   Vancouver, BC, Canada, June 16th 2023 - Defence Therapeutics Inc. (“Defence” or the “Company”), a Canadian biopharmaceutical company spec...
Defence Therapeutics Inc.
About the publication
06 June 2023 08:00AM
Defence Therapeutics Inc.: DEFENCE BEGINS TESTING ITS ARM VACCINE AGAINST PANCREATIC CANCER
CA24463V1013
                                                                    _________________________________________________________________CSE: DTC             FSE: DTC             USOTC: DTCFF  PRESS RELEASEDEFENCE BEGINS TESTING ITS ARM VACCINE AGAINST PANCREATIC CANCERVancouver, BC, Canada, June 6, 2023 - Defence Therapeutics Inc. (“Defence” or the “C...
Defence Therapeutics Inc.
About the publication
06 June 2023 08:00AM
DEFENCE BEGINS TESTING ITS ARM VACCINE AGAINST PANCREATIC CANCER
CA24463V1013
                                                                    _________________________________________________________________CSE: DTC             FSE: DTC             USOTC: DTCFF  PRESS RELEASEDEFENCE BEGINS TESTING ITS ARM VACCINE AGAINST PANCREATIC CANCERVancouver, BC, Canada, June 6, 2023 - Defence Therapeutics Inc. (“Defence” or the “C...
Defence Therapeutics Inc.
About the publication
24 May 2023 08:00AM
DEFENCE’S ARM VACCINE CURED 100% OF ANIMALS WITH PRE-ESTABLISHED LYMPHOMA
CA24463V1013
  _________________________________________________________________ CSE: DTC  FSE: DTC  USOTC: DTCFF  PRESS RELEASE     BREAKTHROUGH RESULTS: DEFENCE’S ARM VACCINE CURED 100% OF ANIMALS WITH PRE-ESTABLISHED LYMPHOMA   Vancouver, BC, Canada, May 24th 2023 - Defence Therapeutics Inc. (“Defence” or the “Company”), a Canadian biopharmaceutical c...
Defence Therapeutics Inc.
About the publication
24 May 2023 08:00AM
Defence Therapeutics Inc.: BREAKTHROUGH RESULTS: DEFENCE’S ARM VACCINE CURED 100% OF ANIMALS WITH PRE-ESTABLISHED LYMPHOMA
CA24463V1013
  _________________________________________________________________ CSE: DTC  FSE: DTC  USOTC: DTCFF  PRESS RELEASE     BREAKTHROUGH RESULTS: DEFENCE’S ARM VACCINE CURED 100% OF ANIMALS WITH PRE-ESTABLISHED LYMPHOMA   Vancouver, BC, Canada, May 24th 2023 - Defence Therapeutics Inc. (“Defence” or the “Company”), a Canadian biopharmaceutical c...
Defence Therapeutics Inc.
About the publication
02 May 2023 08:00AM
Defence Therapeutics Inc.: DEFENCE’S SUCCESFULL ACCUTOXTM PRE-CLINICAL EFFICACY STUDY COMPLETE READY FOR PHASE I IND FILING
CA24463V1013
  _________________________________________________________________ CSE: DTC  FSE: DTC  USOTC: DTCFF  PRESS RELEASE     DEFENCE’S SUCCESFULL ACCUTOXTM PRE-CLINICAL EFFICACY STUDY COMPLETE READY FOR PHASE I IND FILING   Vancouver, BC, Canada, May 2nd, 2023 - Defence Therapeutics Inc. (“Defence” or the “Company”), a Canadian biopharmaceutical ...
Defence Therapeutics Inc.
About the publication
02 May 2023 08:00AM
DEFENCE’S SUCCESFULL ACCUTOXTM PRE-CLINICAL EFFICACY STUDY COMPLETE READY FOR PHASE I IND FILING
CA24463V1013
  _________________________________________________________________ CSE: DTC  FSE: DTC  USOTC: DTCFF  PRESS RELEASE     DEFENCE’S SUCCESFULL ACCUTOXTM PRE-CLINICAL EFFICACY STUDY COMPLETE READY FOR PHASE I IND FILING   Vancouver, BC, Canada, May 2nd, 2023 - Defence Therapeutics Inc. (“Defence” or the “Company”), a Canadian biopharmaceutical ...
Defence Therapeutics Inc.
About the publication
27 April 2023 08:00AM
Defence Therapeutics Inc.: USPTO GRANTS TRADEMARK REGISTRATION FOR DEFENCE THERAPEUTICS®
CA24463V1013
CSE: DTC       FSE: DTC       USOTC: DTCFF       PRESS RELEASE   USPTO GRANTS TRADEMARK REGISTRATION FOR DEFENCE THERAPEUTICS® Vancouver, BC, Canada, April 27, 2023 - Defence Therapeutics Inc. (“Defence” or the “Company”), a Canadian biopharmaceutical company developing novel immune-oncology vaccines and drug delivery technologies, is pleased to...
Defence Therapeutics Inc.
About the publication
27 April 2023 08:00AM
USPTO GRANTS TRADEMARK REGISTRATION FOR DEFENCE THERAPEUTICS®
CA24463V1013
CSE: DTC       FSE: DTC       USOTC: DTCFF       PRESS RELEASE   USPTO GRANTS TRADEMARK REGISTRATION FOR DEFENCE THERAPEUTICS® Vancouver, BC, Canada, April 27, 2023 - Defence Therapeutics Inc. (“Defence” or the “Company”), a Canadian biopharmaceutical company developing novel immune-oncology vaccines and drug delivery technologies, is pleased to...
Defence Therapeutics Inc.
About the publication
24 April 2023 08:00AM
DEFENCE GRANTED US PATENT WITH BROAD COVERAGE ON ACCUMTM-BASED VACCINE ENHANCER PLATFORM TECHNOLOGY
CA24463V1013
  _________________________________________________________________ CSE: DTC  FSE: DTC  USOTC: DTCFF  PRESS RELEASE     DEFENCE GRANTED US PATENT WITH BROAD COVERAGE ON ACCUMTM-BASED VACCINE ENHANCER PLATFORM TECHNOLOGY   Vancouver, BC, Canada, April 24, 2023 - Defence Therapeutics Inc. (“Defence” or the “Company”), a Canadian biopharmaceut...
Defence Therapeutics Inc.
About the publication
24 April 2023 08:00AM
Defence Therapeutics Inc.: DEFENCE GRANTED US PATENT WITH BROAD COVERAGE ON ACCUMTM-BASED VACCINE ENHANCER PLATFORM TECHNOLOGY
CA24463V1013
  _________________________________________________________________ CSE: DTC  FSE: DTC  USOTC: DTCFF  PRESS RELEASE     DEFENCE GRANTED US PATENT WITH BROAD COVERAGE ON ACCUMTM-BASED VACCINE ENHANCER PLATFORM TECHNOLOGY   Vancouver, BC, Canada, April 24, 2023 - Defence Therapeutics Inc. (“Defence” or the “Company”), a Canadian biopharmaceut...
Defence Therapeutics Inc.
About the publication
17 April 2023 08:00AM
Defence Therapeutics Inc.: DEFENCE'S NOVEL ACCUMTM-mRNA VACCINE NOW ADMINISTERED FOR TESTING ON CANCER
CA24463V1013
  _________________________________________________________________ CSE: DTC  FSE: DTC  USOTC: DTCFF  PRESS RELEASE     DEFENCE'S NOVEL ACCUMTM-mRNA VACCINE NOW ADMINISTERED FOR TESTING ON CANCER   Vancouver, BC, Canada, April 17th, 2023 - Defence Therapeutics Inc. (“Defence” or the “Company”), a Canadian biopharmaceutical company specialize...
Defence Therapeutics Inc.
About the publication
17 April 2023 08:00AM
DEFENCE'S NOVEL ACCUMTM-mRNA VACCINE NOW ADMINISTERED FOR TESTING ON CANCER
CA24463V1013
  _________________________________________________________________ CSE: DTC  FSE: DTC  USOTC: DTCFF  PRESS RELEASE     DEFENCE'S NOVEL ACCUMTM-mRNA VACCINE NOW ADMINISTERED FOR TESTING ON CANCER   Vancouver, BC, Canada, April 17th, 2023 - Defence Therapeutics Inc. (“Defence” or the “Company”), a Canadian biopharmaceutical company specialize...
Defence Therapeutics Inc.
About the publication
11 April 2023 08:00AM
SUCCESSFULLY ENGINEERED ACCUM(TM) -mRNA VACCINE CREATING A NEW VACCINE PLATFORM. THE IN VIVO ACCUM(TM)-mRNA CANCER VACCINE PROGRAM BEGINS
CA24463V1013
CSE: DTC       FSE: DTC       USOTC: DTCFF       PRESS RELEASE  DEFENCE BREAKTHROUGH: SUCCESSFULLY ENGINEERED ACCUMTM -mRNA VACCINE CREATING A NEW VACCINE PLATFORM. THE IN VIVO ACCUMTM-mRNA CANCER VACCINE PROGRAM BEGINS Vancouver, BC, Canada, April 11th, 2023 - Defence Therapeutics Inc. (“Defence” or the “Company”), a Canadian biopharmaceutical c...
Defence Therapeutics Inc.
About the publication
11 April 2023 08:00AM
DEFENCE BREAKTHROUGH: SUCCESSFULLY ENGINEERED ACCUM(TM) -mRNA VACCINE CREATING A NEW VACCINE PLATFORM. THE IN VIVO ACCUM(TM)-mRNA CANCER VACCINE PROGRAM BEGINS
CA24463V1013
CSE: DTC       FSE: DTC       USOTC: DTCFF       PRESS RELEASE  DEFENCE BREAKTHROUGH: SUCCESSFULLY ENGINEERED ACCUMTM -mRNA VACCINE CREATING A NEW VACCINE PLATFORM. THE IN VIVO ACCUMTM-mRNA CANCER VACCINE PROGRAM BEGINS Vancouver, BC, Canada, April 11th, 2023 - Defence Therapeutics Inc. (“Defence” or the “Company”), a Canadian biopharmaceutical c...
Defence Therapeutics Inc.
About the publication
28 March 2023 08:00AM
DEFENCE TO COMPLETE A FINAL PRE-CLINICAL STUDY PRIOR TO IND FILINGS FOR THE ACCUTOXTM PHASE I CANCER TRIAL AT THE CITY OF HOPE NATIONAL MEDICAL CENTER AND BECKMAN RESEARCH INSTITUTE
CA24463V1013
  _________________________________________________________________ CSE: DTC  FSE: DTC  USOTC: DTCFF  PRESS RELEASE     DEFENCE TO COMPLETE A FINAL PRE-CLINICAL STUDY PRIOR TO IND FILINGS FOR THE ACCUTOXTM PHASE I CANCER TRIAL AT THE CITY OF HOPE NATIONAL MEDICAL CENTER AND BECKMAN RESEARCH INSTITUTE   Vancouver, BC, Canada, March 28th 2023 ...
Defence Therapeutics Inc.
About the publication
28 March 2023 08:00AM
DEFENCE TO COMPLETE A FINAL PRE-CLINICAL STUDY PRIOR TO IND FILINGS FOR THE ACCUTOXTM PHASE I CANCER TRIAL AT THE CITY OF HOPE NATIONAL MEDICAL CENTER AND BECKMAN RESEARCH INSTITUTE
CA24463V1013
  _________________________________________________________________ CSE: DTC  FSE: DTC  USOTC: DTCFF  PRESS RELEASE     DEFENCE TO COMPLETE A FINAL PRE-CLINICAL STUDY PRIOR TO IND FILINGS FOR THE ACCUTOXTM PHASE I CANCER TRIAL AT THE CITY OF HOPE NATIONAL MEDICAL CENTER AND BECKMAN RESEARCH INSTITUTE   Vancouver, BC, Canada, March 28th 2023 ...
Defence Therapeutics Inc.
About the publication
14 March 2023 08:00AM
DEFENCE THERAPEUTICS SIGNS COLLABORATION AGREEMENT WITH ORANO TO DEVELOP THE NEXT GENERATION OF TARGETED RADIO-IMMUNOTHERAPY FOR CANCER
CA24463V1013
  _________________________________________________________________ CSE: DTC  FSE: DTC  USOTC: DTCFF  PRESS RELEASE     DEFENCE THERAPEUTICS SIGNS COLLABORATION AGREEMENT WITH ORANO TO DEVELOP THE NEXT GENERATION OF TARGETED RADIO-IMMUNOTHERAPY FOR CANCER   Vancouver, BC, Canada, March 14, 2023 – Defence Therapeutics Inc. (“Defence” or the “...
Defence Therapeutics Inc.
About the publication
14 March 2023 08:00AM
DEFENCE THERAPEUTICS SIGNS COLLABORATION AGREEMENT WITH ORANO TO DEVELOP THE NEXT GENERATION OF TARGETED RADIO-IMMUNOTHERAPY FOR CANCER
CA24463V1013
  _________________________________________________________________ CSE: DTC  FSE: DTC  USOTC: DTCFF  PRESS RELEASE     DEFENCE THERAPEUTICS SIGNS COLLABORATION AGREEMENT WITH ORANO TO DEVELOP THE NEXT GENERATION OF TARGETED RADIO-IMMUNOTHERAPY FOR CANCER   Vancouver, BC, Canada, March 14, 2023 – Defence Therapeutics Inc. (“Defence” or the “...
Defence Therapeutics Inc.
About the publication
27 February 2023 08:00AM
DEFENCE’S PIPELINE ADVANCES TO MULTIPLE PHASE I CLINICAL TRIALS
CA24463V1013
  _________________________________________________________________ CSE: DTC  FSE: DTC  USOTC: DTCFF  PRESS RELEASE       DEFENCE’S PIPELINE ADVANCES TO MULTIPLE PHASE I CLINICAL TRIALS   Vancouver, BC, Canada, February 27th, 2023 - Defence Therapeutics Inc. (“Defence” or the “Company”), a Canadian biopharmaceutical company specialized in t...
Defence Therapeutics Inc.
About the publication
27 February 2023 08:00AM
DEFENCE’S PIPELINE ADVANCES TO MULTIPLE PHASE I CLINICAL TRIALS
CA24463V1013
  _________________________________________________________________ CSE: DTC  FSE: DTC  USOTC: DTCFF  PRESS RELEASE       DEFENCE’S PIPELINE ADVANCES TO MULTIPLE PHASE I CLINICAL TRIALS   Vancouver, BC, Canada, February 27th, 2023 - Defence Therapeutics Inc. (“Defence” or the “Company”), a Canadian biopharmaceutical company specialized in t...
Defence Therapeutics Inc.
About the publication
More Defence Therapeutics Inc. related information
Type Total Last Made by Go to
Corporate Research 6 16th May 2022 EQS Group AG Corporate Research
Directors Dealings 0 - - DD
Short Seller (DE) 0 - - SSR (DE)
Short Seller (UK) 0 - - SSR (UK)
Disclaimer:

The combination of information with graphic elements makes an important contribution to visual orientation and navigation through complex factual topics. Essential content features can be perceived, grasped and contextually processed much faster. 
The figurative marks, logos and other graphic and textual elements used on this website are for illustrative purposes only. All rights to the aforementioned elements are held by their respective owners. They are used without the intention of copyright infringement or intellectual property infringement.

If you believe that copyrights or intellectual property have been infringed by the choice of illustration, please contact us immediately to clarify the issue.

v.07062023 EN